CAR-T cell therapy for cancer causes 'brain fog,' study shows
- A 2025 study led by Michelle Monje at Stanford Medicine revealed that treatment with CAR-T cells may lead to subtle cognitive difficulties, commonly referred to as "brain fog," in cancer patients.
- This discovery follows reports from Swedish and other research showing CAR-T's improved survival in blood cancers but emerging concerns over cognitive side effects independent of other treatments.
- Researchers identified microglia-driven inflammation damaging oligodendrocytes and myelin, which support cognitive function, as a mechanism linking CAR-T therapy to brain fog.
- In mice, Monje's team reversed impairment using compounds targeting microglia or chemokine signals, highlighting a potential soon-available treatment to improve patients' quality of life.
- This newly recognized immunotherapy-related cognitive syndrome implies a need for further research to develop therapies addressing long-term effects while acknowledging CAR-T's life-saving impact.
19 Articles
19 Articles
CAR T Cell Therapy Trial Shows Promise in Fighting Solid Tumors
Less than 10 years ago, NPR’s Rob Stein was reporting on what he described as “among the most exciting developments in cancer research in years” — a type of treatment known as CAR T cells. That’s an acronym for “chimeric antigen receptor,” and, as the National Cancer Institute pointed out, they’re made using a patient’s T cells, which can bolster their ability to fight cancer within that person’s body.Now, a new clinical trial indicates that CAR…
New Zealand promotes expensive cancer therapy while at the same time promoting one of the causes of cancer
New Zealand’s Stuff newspaper has been publishing a series of articles about using CAR T-cell therapy to treat lymphatic cancers. New Zealand has the highest rate of lymphoma in the world. In […] The post New Zealand promotes expensive cancer therapy while at the same time promoting one of the causes of cancer first appeared on The Expose.
CAR T-Cell Therapy for Relapsed/Refractory Follicular Lymphoma
(MedPage Today) -- When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and lengthy survival outcomes...
Survey shows majority of Americans unaware of innovative cancer treatment
BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy. The little known, but highly promising technology breakthrough makes it possible for your body to fight cancer, often without invasive surgery, offering patients new hope for the possibility of long-term remission. However, a new survey by Roswell Park Comprehensive Cancer Center of 1,021 adults in the U…
Coverage Details
Bias Distribution
- 86% of the sources are Center
To view factuality data please Upgrade to Premium